CPHI Stock Overview
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
China Pharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.32 |
| 52 Week High | US$2.70 |
| 52 Week Low | US$0.27 |
| Beta | 0.91 |
| 1 Month Change | -17.83% |
| 3 Month Change | -32.98% |
| 1 Year Change | -79.49% |
| 3 Year Change | -99.23% |
| 5 Year Change | -98.09% |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPHI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.3% | 0.08% | 1.2% |
| 1Y | -79.5% | 13.2% | 24.9% |
Price Volatility
| CPHI volatility | |
|---|---|
| CPHI Average Weekly Movement | 14.0% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CPHI's share price has been volatile over the past 3 months.
Volatility Over Time: CPHI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 231 | Zhilin Li | www.chinapharmaholdings.com |
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People’s Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.
China Pharma Holdings, Inc. Fundamentals Summary
| CPHI fundamental statistics | |
|---|---|
| Market cap | US$4.70m |
| Earnings (TTM) | -US$3.08m |
| Revenue (TTM) | US$7.01m |
0.7x
P/S Ratio-1.5x
P/E RatioIs CPHI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPHI income statement (TTM) | |
|---|---|
| Revenue | US$7.01m |
| Cost of Revenue | US$7.29m |
| Gross Profit | -US$281.08k |
| Other Expenses | US$2.80m |
| Earnings | -US$3.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | -4.01% |
| Net Profit Margin | -43.91% |
| Debt/Equity Ratio | 60.6% |
How did CPHI perform over the long term?
See historical performance and comparison